ARGENX
LIVE

Serial Number

98957449

Owner

Argenx B.V.

Attorney

Edward T. White

First Use Date

Dec 17, 2021

Filing Date

Jan 13, 2025

Add to watchlist:

No watchlists yet
View on USPTO

ARGENX Trademark

Serial Number: 98957449 • Registration: 8290605

ARGENX is a trademark filed by Argenx B.V. on January 13, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Argenx B.V. (4 trademarks)

Industriepark Zwijnaarde 7
Zwijnaarde B-9052 , BE

Entity Type: 99

Trademark Details

Filing Date

January 13, 2025

Registration Date

June 9, 2026

First Use Anywhere

December 17, 2021

First Use in Commerce

December 17, 2021

Published for Opposition

April 21, 2026

Goods & Services

Wholesale and retail store services for therapeutic pharmaceutical preparations in the field of immunology and auto-immune diseases and antibodies or fragments or derivatives of antibodies with therapeutic properties; business administrative services in relation to patient information in the field of immunology, diseases of the immune system and antibody therapeutics; business administration of patient reimbursement programs

Providing information to patients in the field of auto-immune, antibody-mediated, neuromuscular, hematological, inflammatory, respiratory, kidney, skin, and transplantation-related diseases and disorders, cancer and diseases of the immune system and the treatment thereof; medical consultancy and information services relating to therapeutic biopharmaceutical products; Provision of medical information on therapeutic pharmaceutical, medical, and healthcare products to customers or patients through an online computer network

Research and development in the field of immunology, antibody engineering and autoimmune diseases for therapeutic purposes; therapeutic drug research and development in the field of immunology, antibody technology and autoimmune diseases; scientific and technological services, namely, research relating to immunity, autoimmune diseases and antibody engineering for therapeutic purposes; providing medical and scientific research information in the field of therapeutic pharmaceuticals, clinical trials, research and development

Pharmaceuticals and medical preparations for therapeutic purposes in the field of immunology and autoimmune diseases; pharmaceutical preparations for the prevention or treatment of autoimmune, antibody-mediated, neuromuscular, hematological, inflammatory, respiratory, kidney, skin, and transplantation-related diseases and disorders, cancer and diseases of the immune system; compositions of antibodies or fragments of antibodies or derivatives of antibodies with therapeutic properties; antibodies or fragments of antibodies or derivatives of antibodies for the prevention or treatment of autoimmune, antibody-mediated, neuromuscular, hematological, inflammatory, respiratory, kidney, skin, transplantation-related diseases and disorders, cancer and diseases of the immune system

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jun 9, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jun 9, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 21, 2026 NPUB
PUBLISHED FOR OPPOSITION
Apr 21, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 15, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 25, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 19, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 19, 2026 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Mar 19, 2026 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Feb 13, 2026 GNS3
LETTER OF SUSPENSION E-MAILED
Feb 13, 2026 GNSL
SUSPENSION LETTER WRITTEN
Feb 13, 2026 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 19, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 19, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 19, 2025 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Sep 17, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Sep 17, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 19, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jun 19, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jun 19, 2025 CNRT
ASSIGNED TO EXAMINER
Jun 19, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 11, 2025 NWOS
NEW APPLICATION ENTERED
Jan 13, 2025 NWAP